




**Scholars'
Press**

Ly Le

**Incorporating Molecular
Dynamics Simulations into
Drug Design**

Ly Le

Incorporating Molecular Dynamics Simulations into Drug Design



Scholar's Press

Impressum / Imprint

Bibliografische Information der Deutschen Nationalbibliothek: Die Deutsche Nationalbibliothek verzeichnet diese Publikation in der Deutschen Nationalbibliografie; detaillierte bibliografische Daten sind im Internet über <http://dnb.d-nb.de> abrufbar.

Alle in diesem Buch genannten Marken und Produktnamen unterliegen warenzeichen-, marken- oder patentrechtlichem Schutz bzw. sind Warenzeichen oder eingetragene Warenzeichen der jeweiligen Inhaber. Die Wiedergabe von Marken, Produktnamen, Gebrauchsnamen, Handelsnamen, Warenbezeichnungen u.s.w. in diesem Werk berechtigt auch ohne besondere Kennzeichnung nicht zu der Annahme, dass solche Namen im Sinne der Warenzeichen- und Markenschutzgesetzgebung als frei zu betrachten wären und daher von jedermann benutzt werden dürften.

Bibliographic information published by the Deutsche Nationalbibliothek: The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available in the Internet at <http://dnb.d-nb.de>.

Any brand names and product names mentioned in this book are subject to trademark, brand or patent protection and are trademarks or registered trademarks of their respective holders. The use of brand names, product names, common names, trade names, product descriptions etc. even without a particular marking in this work is in no way to be construed to mean that such names may be regarded as unrestricted in respect of trademark and brand protection legislation and could thus be used by anyone.

Coverbild / Cover image: www.ingimage.com

Verlag / Publisher:

Scholar's Press

ist ein Imprint der / is a trademark of

OmniScriptum GmbH & Co. KG

Heinrich-Böcking-Str. 6-8, 66121 Saarbrücken, Deutschland / Germany

Email: info@scholars-press.com

Herstellung: siehe letzte Seite /

Printed at: see last page

ISBN: 978-3-639-71625-2

Zugl. / Approved by: Salt Lake City, University of Utah, 2011

Copyright © 2014 OmniScriptum GmbH & Co. KG

Alle Rechte vorbehalten. / All rights reserved. Saarbrücken 2014

Ly Le

Incorporating Molecular Dynamics Simulations into Drug Design

**INCORPORATING MOLECULAR DYNAMICS SIMULATIONS INTO DRUG
DESIGN TARGETING INFLUENZA N1 NEURAMINIDASES**

by
Ly Le

A dissertation submitted to the faculty of
The University of Utah
in partial fulfillment of the requirements for the degree of

Doctor of Philosophy

Department of Chemistry
The University of Utah
December 2010

Copyright © Ly Le 2010

All Rights Reserved

ABSTRACT

The FDA antiviral drug, Tamiflu (oseltamivir)¹ is the front-line antiviral drug for the fight against 2003 avian flu (H5N1)² as well as, more recently, for the 2009 swine flu (H1N1pdm).³ The drug functions as a neuraminidase inhibitor that prevents the release of new virions. Unfortunately, there is emerging evidence that the neuraminidase mutations H274Y and N294S⁴ render oseltamivir ineffective against the H5N1 virus. Of greater concern is the growing likelihood of the emergence of similar oseltamivir-resistant strains of H1N1pdm. It is therefore critical to understand the mechanisms for mutation-induced drug resistance in the H5N1 and H1N1pdm flu viruses in order to develop new and effective therapies. As molecular dynamics (MD) simulations have become an important tool for the study of biological systems, this dissertation aims to employ MD simulations for computer-aided rational drug design. Specifically, different MD simulation techniques were utilized in the investigation of oseltamivir-resistant mechanisms of H5N1/H1N1pdm and for the development of new antiviral drugs.

Chapter 1 is simply a general introduction to the whole thesis. Chapter 2 presents top-hits for H1N1pdm neuraminidase identified by virtual screening using ensemble-based docking technique, which incorporates protein flexibility into molecular docking. Next in Chapter 3, progress in the development of two related methodologies for calculation of solvation free energy, one called the Coupled Reference Interaction Site model-hyper-netted chain/molecular dynamics (RISM/MD) approach, and another called Molecular Mechanics Poisson-Boltzmann linear response approximation and surface area contributions (MMPB-LRA-SA), are presented. The methods are expected to be applicable to the lead refinement process since they provide more reliable results than the continuum model but are less computationally expensive than conventional MD methods. In Chapter 4, we discuss our observations based on drug-protein endpoint interactions on how the mutations H274Y and N294S induce oseltamivir resistance in neuraminidase N1 subtypes. However, since the two mutations are non-active-site,

endpoint interactions alone cannot fully account for the drug resistance. In Chapter 5, we present our finding of the drug binding pathway through electrostatic surface potential and steered MD simulation.⁵ The results reveal a novel oseltamivir-resistant mechanism in which the mutations rupture the drug binding funnel, in conjunction with the findings reported in Chapter 4. Our study not only assists understanding of oseltamivir-resistance in neuraminidase N1 subtypes, but also bears several important consequences for the intelligent design of new inhibitors that can overcome the established resistance strain.

CONTENTS

ABSTRACT.....	3
LIST OF FIGURES.....	7
LIST OF TABLES.....	10
ACKNOWLEDGMENTS.....	12
1. GENERAL INTRODUCTION	15
2. PROMISING ANTIVIRAL DRUGS FOR SWINE FLU H1N1PDM REVEALED BY VIRTUAL SCREENING 20USING ENSEMBLE-BASED DOCKING.....	20
2.1 Receptor	20
2.1.1 Molecular model of H1N1dpm neuraminidase.....	20
2.1.2 MD simulation of ionized oseltamivir-neuraminidase complex	23
2.2 Ligands.....	25
2.3 Molecular docking	26
2.4. Results and discussion	28
2.4.1 Comparing binding modes of oseltamivir from molecular docking and MD simulation	28
2.4.2. Ranking of the top binding compounds	31
2.4.3. Hydrogen bond analysis of top binding compounds.....	43
2.5. Conclusion	47
3. NEW APPROACHES FOR SOLVATION FREE ENERGY CALCULATION	49
3.1 Improving the performance of the coupled reference interaction site model – hyper-netted chain (RISM-HNC) / MD method for free energy of solvation	49
3.1.1 Introduction of RISM-HNC/MD.....	49
3.1.2 Using the hard-sphere (HS) free energy as the reference and a linear response approximation (LRA) to improve the performance of the RISM-HNC/MD method	50
3.1.3 Methodology assessment.....	51
3.1.4 Conclusion and outlook.....	54
3.2 Explicitly-solvated ligand contribution to continuum solvation models for binding free energies: Selectivity of theophylline binding to an RNA aptamer....	56
3.2.1 Introduction of MM-PB/LRA-SA	56
3.2.2 Using MM-PB/LRA-SA to study selectivity of Theophylline binding to an RNA aptamer.....	57

3.2.3 Conclusion and outlook	62
4. MOLECULAR MODELING OF MUTATION-INDUCED OSELTAMIVIR DRUG RESISTANCE FOR INFLUENZA N1 NEURAMINIDASES..	64
4.1 Literature review of oseltamivir-resistance and our proposed study	64
4.2 Computational details	65
4.3 Results and discussion	66
4.4 Conclusion and outlook	75
5. AN ELECTROSTATIC FUNNEL DIRECTS BINDING OF OSELTAMIVIR TO INFLUENZA N1 SUBTYPE NEURAMINDASES	78
5.1 Characteristics of the electrostatic surface potential of N1 Neuraminidases shed light for further study on drug binding and drug resistance	78
5.2 Computational details	80
5.3 Results	82
5.4 Discussion and future studies	89
5.5 Supplementary information	92
APPENDIX	93
REFERENCES.....	96

LIST OF FIGURES

1.1 Oseltamivir functions as a neuraminidase inhibitor, preventing the release of new swine flu H1N1pdm viruses.	16
2.1 Discrete optimized protein energy (DOPE) per-residue of homology and molecular model of H1N1pdm neuraminidase in comparison with that of template avian H5N1 neuraminidase.	21
2.2 Schematic representations of drug-bound simulation systems.	22
2.3 The 13 representative ensembles resulting from clustering analysis, accounting for 96.2% of the configuration space, are ordered by the corresponding simulation time	24
2.4 Overlapping structures of the four most populated clusters in Figure 2.3	25
2.5 Oseltamivir docked in SA cavity of H1N1pdm neuraminidase as compared to that from MD simulation, as shown in black with no hydrogen.	29
2.6 Binding energies of 33 compounds are listed with their NSC ID.	32
2.7 Binding energy spectra vs. simulation time of zanamivir, oseltamivir and peramivir.	43
2.8 Peramivir (A) and zanamivir (B) docked in the H1N1pdm neuraminidase structure.	45
2.9 Docked structure of top-hits against swine flu neuraminidase	46
3.1 Chemical structures of theophylline (A) and derivatives, 1-methylxanthine (B), 3-methylxanthine (C), xanthine (D) and caffeine (E).	59

3.2 Conformation of theophylline-bound RNA aptamer after MD simulation, with triples labeled by residue and distinguished by separate colors, visualized using the Pymol viewing program.56 Grey balls represent Mg ²⁺ ions.	59
3.3 Relative binding free energies calculated by (A) MM-PBSA and (B) MM-PB/LRA-SA for the 5 theophylline analogues compared with experimental data, showing linear fits of data with R ² values.....	62
4.1 Root mean squared deviation (RMSD) of WT and mutant avian H5N1 and swine H1N1pdm neuraminidases across six 20 ns production simulations	67
4.2 Network and occupancy of hydrogen bonds stabilizing oseltamivir in the sialic acid binding pocket of wild type and drug-resistant mutant avian H5N1 neuraminidases	69
4.3 Network and occupancy of hydrogen bonds stabilizing oseltamivir in the sialic acid binding pocket of wild type and drug-resistant mutant avian H1N1pdm neuraminidases	70
4.4. The solvent accessible surface area of oseltamivir's pentyl group (PG-SASA) in H5N1 and H1N1pdm wild type and mutant simulations	73
4.5 Electrostatic surface potential of avian H5N1 and swine H1N1pdm neuraminidases in oseltamivir-bound simulations, revealing a positively charged pathway into the binding pocket	76
5.1 Electrostatic surface potential of the SA binding pocket of H1N1pdm and oseltamivir	79
5.2 Distances between hydrogen bond acceptor-donor pairs between oseltamivir and active site amino acids vs. simulation time in simSMD1	83
5.3 Forced unbinding of oseltamivir from H5N1 neuraminidase	83

5.4 Oseltamivir in “flipped” position (position of oseltamivir at 7.5ns in simSMD1) in comparison with its stable equilibrium position, shown with the electrostatic surface potential of the protein84

5.5 Escape of oseltamivir from H5N1 neuraminidase in equilibrium simulations from simFEQ1 and simFEQ4.....87

5.6 Escape and rebinding of oseltamivir through the electrostatic binding funnel in H5N1 neuraminidase.....89

LIST OF TABLES

2.1 RMSD of the binding structures of oseltamivir from docking results in the 13 receptor ensembles compared to those extracted from the 20ns MD simulation. Also listed are the percent of population of the receptor ensemble, the percent contribution of the 20 ns MD simulation, and the percent population of the largest docked oseltamivir cluster.....	30
2.2 Docking results for 33 compounds ranked by harmonic mean of binding energy. The first column is the final rank and also the compound ID. The predicted K_i calculated according to the harmonic mean binding free energies are also shown, as well as the arithmetic mean binding free energies and their corresponding standard deviations. 33	
2.3 The frequency of hydrogen bond (in percent) for binding site residues with known drugs and top binding compounds utilizing the hydrogen bond distance and angle cutoffs of 3.5Å and 45°, respectively.	44
3.1. Free energies of solvation (kcal/mol) calculated by coupled RISM-HNC/ MD compared to experimental values, FEP values, and stand-alone RISM-HNC results of Sato et al.	52
3.2 Free energies of solvation (kcal/mol) calculated by coupled RISM-HNC/ MD compared to experimental values, and those of Wan et al.	53
3.3 Free energies of solvation (kcal/mol) calculated by coupled RISM-HNC/ MD with the GAFF force field and HF/3-21G charges, compared to experimental values. 54	
4.1 Summary of simulations. The “ensemble” column lists the variables held constant during the simulations; N, p and T correspond to the number of atoms, pressure, and	

temperature, respectively. The simulation times reflect a 20 ns setup/equilibration run followed by a 20 ns production run.....74

5.1 Summary of simulations. The “Structure” column lists the type of neuraminidase, associated mutations, and drug modeled in each system.80

5.2 Summary of FEQ1-10 simulations starting from “flipped” position of oseltamivir taken from simSMD1 at 7.5 ns.....86

ACKNOWLEDGMENTS

First, I am very grateful to my advisor Prof. Thanh N. Truong for his tremendous support during my PhD study. Second, I would especially like to thank Prof. Klaus Schulten for giving me an invaluable opportunity to collaborate with his research group where I had a chance to immerse myself to an exceptionally professional and challenging environment and learn a great deal from that.

Many thanks to all of my past instructors at the University of Utah who made significant contributions to my training. I would like to especially thank Dr. Holly Freedman for explaining to me insights into different methods for free energy of solvation and teaching me how to run an MD simulation for the very first time, Dr. Zingfa Xiao for teaching me homology modeling and docking, Prof. Valeria Molinero for teaching me coarse-grained modeling. At the University of Illinois at Urbana Champaign, I am greatly indebted to Dr. Eric Lee for teaching me SMD simulations and also working closely with me on the “swine flu” project. I would also like to thank Dr. Saam Jan for teaching me drug parameterization.

I am sincerely grateful to my committee members: to Prof. Greg Voth for helping me to put my research plan into perspective, to Prof. Tom Cheatham for teaching me molecular modeling and allowing me to attend his group meeting to gain more experience in the subject, and to Prof. Jack Simons for teaching me how to design QM/MM experiments for my proposal defense.

I also appreciate the help I have received from many other faculty and staff, especially Prof. Michael Morse and Ms. Jo Hoovey from the Department of Chemistry, Dr. Martin Cuma from the Center for High Performance Computing.